重症监护病房抗NMDAR脑炎中多价静脉免疫球蛋白与治疗性血浆置换的疗效比较
该回顾性观察研究纳入2007年1月至2022年12月在某三级医疗神经重症监护病房住院的37例重症抗NMDAR脑炎患者,按一线免疫调节方案(均联合糖皮质激素)分为单用治疗性血浆置换组8例、单用静脉免疫球蛋白组13例、静脉免疫球蛋白后序贯治疗性血浆置换组16例。主要终点为一线免疫调节治疗的有效性,定义为未启用其他免疫调节治疗且同时满足对简单指令有反应、无癫痫发作、无异常运动三个条件。单用治疗性血浆置换的8例全部改善,应答中位潜伏期31天;29例接受静脉免疫球蛋白的患者中13例改善,应答中位潜伏期36天,另16例因无改善而转换为治疗性血浆置换,应答中位潜伏期30天。治疗性血浆置换显著优于静脉免疫球蛋白。作者认为免疫治疗在NMDAR脑炎患者中可能存在疗效差异,但回顾性分析存在偏倚和混杂,需前瞻性评估。
要点
- 37例重症抗NMDAR脑炎患者中,单用治疗性血浆置换组8例全部改善,应答中位潜伏期31天。
- 29例接受静脉免疫球蛋白的患者中13例改善(应答中位潜伏期36天),16例因无改善转换为治疗性血浆置换(应答中位潜伏期30天)。
- 按一线方案分组:单用治疗性血浆置换8例、单用静脉免疫球蛋白13例、静脉免疫球蛋白后序贯治疗性血浆置换16例。
- 研究结论认为治疗性血浆置换显著优于静脉免疫球蛋白,但为回顾性观察,可能存在偏倚和混杂。
- 作者提出免疫治疗在NMDAR脑炎患者中可能存在疗效差异的假设,认为其治疗潜力值得前瞻性评估。
适用人群与场景
- 某三级医疗神经重症监护病房收治的成人重症抗NMDAR脑炎患者,研究时段为2007年1月至2022年12月。
- 按一线免疫调节方案(均联合糖皮质激素)分为单用治疗性血浆置换、单用静脉免疫球蛋白、静脉免疫球蛋白后序贯治疗性血浆置换三组。
诊断标准与关键阈值
- 主要终点有效性定义:未启用其他免疫调节治疗,且同时满足对简单指令有反应、无癫痫发作、无异常运动三个条件。
处置流程与药物剂量
- 一线免疫调节治疗均联合糖皮质激素,具体剂量、途径和疗程原文未报告。
- 单用治疗性血浆置换组8例,全部改善,应答中位潜伏期31天。
- 单用静脉免疫球蛋白组13例,其中13例改善(应答中位潜伏期36天),16例因无改善转换为治疗性血浆置换(应答中位潜伏期30天)。
- 静脉免疫球蛋白后序贯治疗性血浆置换组共16例。
研究设计与关键结果
- 研究类型为观察性回顾性研究,纳入37例重症抗NMDAR脑炎患者,单中心(某三级医疗神经重症监护病房),研究时段2007年1月至2022年12月。
- 分组:单用治疗性血浆置换8例、单用静脉免疫球蛋白13例、静脉免疫球蛋白后序贯治疗性血浆置换16例。
- 单用治疗性血浆置换组8例全部改善,应答中位潜伏期31天。
- 29例接受静脉免疫球蛋白的患者中13例改善,应答中位潜伏期36天;16例因无改善转换为治疗性血浆置换,应答中位潜伏期30天。
- 治疗性血浆置换显著优于静脉免疫球蛋白。
证据类型、等级与局限
- 证据类型:观察性回顾性研究。
- 作者指出回顾性分析可能存在偏倚和混杂。
- 作者认为免疫治疗在NMDAR脑炎患者中可能存在疗效差异,其治疗潜力值得前瞻性评估。
对床旁实践的改变
- 作者认为免疫治疗在NMDAR脑炎患者中可能存在疗效差异,其治疗潜力值得前瞻性评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Anti-N-methyl D-aspartate-receptor encephalitis (anti-NMDARe) is a severe disease with a favorable outcome when immunomodulatory management is started rapidly. The main objective of this study is to compare the early efficacy of the two most frequently used therapeutics, i.e., intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE), in intensive care patients admitted for anti-NMDARe.
METHODS: This is an observational retrospective study of patients hospitalized in a tertiary medical neurointensive care unit for severe anti-NMDARe. Patients were categorized according to the modality of first-line immunomodulatory therapies associated with corticosteroids: TPE, IVIG, or IVIG followed by TPE. The primary end point was the effectiveness of the first-line immunomodulatory treatment. Treatment was considered effective when no other immunomodulatory therapy was introduced and the patient met the following three conditions: response to simple commands, absence of epileptic seizures, and absence of abnormal movements.
RESULTS: Thirty-seven patients were included in the study from January 2007 to December 2022: 8 were treated with TPE alone, 13 were treated with IVIG alone, and 16 were treated with IVIG followed by TPE. Of the 29 patients treated with IVIG, 13 showed improvement, with a median latency to treatment response of 36 days, whereas 16 were switched to TPE, with a median latency to treatment response of 30 days due to a lack of improvement. All eight patients treated with TPE improved, with a latency to treatment response of 31 days. TPE was significantly more effective than IVIG.
CONCLUSIONS: This study raises the hypothesis that immunotherapies may have differential response rates among patients with NMDARe. Although the retrospective nature of the analysis may be subject to bias and confounding, the potential for therapeutic impact deserves prospective evaluation.
参考来源
- Journaux M, Rohaut B, Ropers J, et al. Comparison of the Efficacy of Polyvalent Intravenous Immunoglobulins and Therapeutic Plasma Exchange in Anti-NMDAR Encephalitis in the ICU. Neurocrit Care. 2025. PMID: 41407987. doi:10.1007/s12028-025-02427-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。